Enliven Therapeutics (NASDAQ:ELVN) Releases Quarterly Earnings Results, Beats Expectations By $0.17 EPS

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.17, Zacks reports.Get Enliven Therapeutics alerts:Enliven Therapeutics Trading Up 6.0 %NASDAQ ELVN traded up $1.31 on Thursday, hitting $23.11. The company's stock had a trading volume of 105,264 shares, compared to its average volume of 266,162. The firm has a market cap of $1.09 billion, a P/E ratio of -11.74 and a beta of 1.10. The company's 50-day simple moving average is $22.77 and its 200 day simple moving average is $20.02. Enliven Therapeutics has a 52-week low of $9.80 and a 52-week high of $27.67. Wall Street Analysts Forecast GrowthA number of brokerages recently weighed in on ELVN. Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an "outperform" rating and a $32.00 target price on the stock. Baird R W upgraded Enliven Therapeutics to a "strong-buy" rating in a report on Tuesday, June 11th.Get Our Latest Research Report on Enliven TherapeuticsInsider Buying and SellingIn other news, COO Anish Patel sold 17,475 shares of the firm's stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $25.07, for a total value of $438,098.25. Following the completion of the transaction, the chief operating officer now owns 376,552 shares in the company, valued at approximately $9,440,158.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, COO Anish Patel sold 17,475 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $25.07, for a total transaction of $438,098.25. Following the completion of the transaction, the chief operating officer now directly owns 376,552 shares in the company, valued at $9,440,158.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph P. Lyssikatos sold 3,099 shares of Enliven Therapeutics stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $27.56, for a total value of $85,408.44. Following the transaction, the insider now owns 1,089,936 shares of the company's stock, valued at approximately $30,038,636.16. The disclosure for this sale can be found here. Insiders sold 123,668 shares of company stock valued at $3,057,633 over the last quarter. 29.20% of the stock is owned by company insiders. About Enliven Therapeutics (Get Free Report)Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.Featured ArticlesFive stocks we like better than Enliven TherapeuticsWhat is a SEC Filing?Michael Burry's Alibaba Bet and the Broader Market ImplicationsDo ETFs Pay Dividends? What You Need to KnowJeff Brown's Exegesis AI Stock PicksInvesting in the High PE Growth Stocks Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta StockThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.→ Elon’s sprint to AI wealth (From InvestorPlace) (Ad)Should you invest $1,000 in Enliven Therapeutics right now?Before you consider Enliven Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here